Neurological complications (NCs) can frequently and significantly affect morbidity and mortality of liver transplant (LT) recipients. We analysed incidence, risk factors, outcome and impact of the immunosuppressive therapy on NC development after LT. We analysed 478 LT in 440 patients, and 93 (19.5%) were followed by NCs. The average LOS was longer in patients experiencing NCs. The 1-, 3- and 5-year graft survival and patient survival were similar in patients with or without a NC. Multivariate analysis showed the following as independent risk factors for NC: a MELD score ≥20 (OR = 1.934, CI = 1.186-3.153) and an immunosuppressive regimen based on calcineurin inhibitors (CNIs) (OR = 1.669, CI = 1.009-2.760). Among patients receiving an everolimus-based immunosuppression, the 7.1% developed NCs, vs. the 16.9% in those receiving a CNI (P = 0.039). There was a 1-, 3- and 5-year NC-free survival of 81.7%, 81.1% and 77.7% in patients receiving a CNI-based regimen and 95.1%, 93.6% and 92.7% in those not receiving a CNI-based regimen (P < 0.001). In patients undergoing a LT and presenting with nonmodifiable risk factors for developing NCs, an immunosuppressive regimen based on CNIs is likely to result in a higher rate of NCs compared to mTOR inhibitors.

Neurological complications after liver transplantation as a consequence of immunosuppression: Univariate and multivariate analysis of risk factors / Rompianesi, G.; Montalti, R.; Cautero, N.; De Ruvo, N.; Stafford, A.; Bronzoni, C.; Ballarin, R.; De Pietri, L.; Di Benedetto, F.; Gerunda, G. E.. - In: TRANSPLANT INTERNATIONAL. - ISSN 0934-0874. - 28:7(2015), pp. 864-869. [10.1111/tri.12564]

Neurological complications after liver transplantation as a consequence of immunosuppression: Univariate and multivariate analysis of risk factors

Rompianesi G.;Cautero N.;Bronzoni C.;Ballarin R.;De Pietri L.;Di Benedetto F.;Gerunda G. E.
2015

Abstract

Neurological complications (NCs) can frequently and significantly affect morbidity and mortality of liver transplant (LT) recipients. We analysed incidence, risk factors, outcome and impact of the immunosuppressive therapy on NC development after LT. We analysed 478 LT in 440 patients, and 93 (19.5%) were followed by NCs. The average LOS was longer in patients experiencing NCs. The 1-, 3- and 5-year graft survival and patient survival were similar in patients with or without a NC. Multivariate analysis showed the following as independent risk factors for NC: a MELD score ≥20 (OR = 1.934, CI = 1.186-3.153) and an immunosuppressive regimen based on calcineurin inhibitors (CNIs) (OR = 1.669, CI = 1.009-2.760). Among patients receiving an everolimus-based immunosuppression, the 7.1% developed NCs, vs. the 16.9% in those receiving a CNI (P = 0.039). There was a 1-, 3- and 5-year NC-free survival of 81.7%, 81.1% and 77.7% in patients receiving a CNI-based regimen and 95.1%, 93.6% and 92.7% in those not receiving a CNI-based regimen (P < 0.001). In patients undergoing a LT and presenting with nonmodifiable risk factors for developing NCs, an immunosuppressive regimen based on CNIs is likely to result in a higher rate of NCs compared to mTOR inhibitors.
2015
28
7
864
869
Neurological complications after liver transplantation as a consequence of immunosuppression: Univariate and multivariate analysis of risk factors / Rompianesi, G.; Montalti, R.; Cautero, N.; De Ruvo, N.; Stafford, A.; Bronzoni, C.; Ballarin, R.; De Pietri, L.; Di Benedetto, F.; Gerunda, G. E.. - In: TRANSPLANT INTERNATIONAL. - ISSN 0934-0874. - 28:7(2015), pp. 864-869. [10.1111/tri.12564]
Rompianesi, G.; Montalti, R.; Cautero, N.; De Ruvo, N.; Stafford, A.; Bronzoni, C.; Ballarin, R.; De Pietri, L.; Di Benedetto, F.; Gerunda, G. E.
File in questo prodotto:
File Dimensione Formato  
tri.12564.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 144.55 kB
Formato Adobe PDF
144.55 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1222730
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 23
  • ???jsp.display-item.citation.isi??? 21
social impact